Europe’s leading independent cannabis company
Bringing together cutting-edge scientific research with the latest innovations in cannabis cultivation, extraction and production.
Cannabis-based products for medical use
Thanks to deep scientific expertise, rigorous process management and quality control, EMMAC ensures MHRA medical-grade quality products with the full accreditation of relevant regulatory certifications for its manufacturing, distribution and supply processes.
In partnership with leading European academic institutions including Imperial College London, EMMAC is at the forefront of research to deliver clinical data regarding the efficacy of medical cannabis for pain and the potential health benefits for patients.
At EMMAC Life Sciences Group, we control the entire lifecycle of our medical cannabis – from cultivation and extraction to production and distribution.
People & expertise
EMMAC’s board and management team comprise of seasoned industry executives and consultants. Every member brings with them a wealth of knowledge and experience – from a range of scientific, medical, technical and FMCG backgrounds.
EMMAC announces pioneering research collaboration with Imperial College London
EMMAC Across Europe
EMMAC has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabis but also a European leader in the production and supply of medical cannabis, hemp and other derivative products.
News & Events
First range of unlicensed medical cannabis products launched; EMMAC’s products already being prescribed to patients in the UK
9 December 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that it is has
19 November 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company is pleased to announce that it has
EMMAC and University of Insubria to present abstract at IACM 10th Conference on Cannabinoid in Medicine
31 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, announces that the manuscript, “Immunomodulatory Effect of
16 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, is pleased to announce that it has
Fill in the form below to receive the latest news and developments in medical cannabis from EMMAC